Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Definitions

• the present invention in the field of biochemistry and medicine is directed to methods and composition for using a glycogen synthase kinase 3, form b (GSK-3 b) inhibitor, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo and thereby treat idiopathic pulmonary fibrosis (IPF).
• a glycogen synthase kinase 3, form b (GSK-3 b) inhibitor most preferably 9-ING-41
• Idiopathic pulmonary fibrosis is a poorly understood progressive and fatal lung disease for which few, if any, treatments exist other than lung transplantation.
• pulmonary fibrosis are not known to be curative and only slow the progression of the disease.
• Median survival time is 3 years after diagnosis (and median survival 5 years after diagnosis is less than 20%).
• Most forms of interstitial lung diseases and other forms of pulmonary fibrosis are characterized by fibrotic lesions, progressive distortion of alveolar architecture occurs and replacement with fibrotic or scar tissues with excess extracellular matrix (ECM) deposition, resulting in progressive dyspnea and loss of lung function.
• ECM extracellular matrix
• GSK-3P is a serine/threonine kinase and is in one of two GSK-3 isoforms (a and b).
• 08K-3b can regulate the function of a diverse list of targets including transcription factors. GSK-3 b also regulates a number of signaling pathways that consequently affect the
• the disclosure is directed to treatment of both pleural and pulmonary fibrosis.
• these methods are achieved via administration of 9-ING-41, which is well tolerated even at high doses. It also limits scar formation in a mouse model of pleural fibrosis and, as described herein, pulmonary fibrosis.
• 9-ING-41 mitigates fibrotic pulmonary remodeling in vivo , addresses the urgent need for effective therapy of pulmonary fibrosis.
• the present invention addresses this important gap and provides novel compounds and methods for targeting fibrotic lung (“FL”) fibroblasts (or myofibroblast)) to effectively treat IPF.
• FL fibrotic lung
• the present invention is directed to a method to inhibit mesomesenchymal transition (MesoMT) of residential pleural mesothelial cells (PMCs) which contributes to expansion of myofibroblasts in the progression to IPF.
• MesoMT mesomesenchymal transition
• PMCs residential pleural mesothelial cells
• the present invention is directed to method of treating idiopathic pulmonary fibrosis (IPF) in a mammalian subject by administering to a mammalian subject in need thereof, an effective amount of a compound of Formula I
• X is independently -H, halo, 5,6-methylenedioxy, -CN, -OMe, -OH, -OBn, -CF 3 , - CH 2 OH, -CH20Me, -CH 2 CH 2 C0 2 H, or -CH 2 CH 2 C0 2 Et; R S - H, lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with -NH 2 ;
• R 2 is -H, lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with -NH 2 ;
• the present invention is also directed to methods of treating IPF in a mammalian subject by administering to a mammalian subject in need thereof, a pharmaceutical composition comprising i) an effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof; and ii) a pharmaceutically acceptable carrier or excipient.
• the present invention is also directed to a method for treating a mammalian subject having or developing a disease or condition characterized by pulmonary fibrosis, most preferably, IPF in humans, comprising administering to the subject an effective amount of a pharmaceutical composition as above.
• the compound or composition preferably comprises 9-ING-41 or an analogue thereof that has at least 20% of the biological or biochemical activity of 9-ING-41 in as in vitro or in vivo assay.
• the most preferable compound is 9-ING-41.
• the compound of Formula I is 9-ING-41 or a pharmaceutically acceptable salt or solvate thereof.
• the mammalian subject is a human.
• the administering is by inhalation.
• composition comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
• the compound or Formula I is preferably 9-ING-41 or a pharmaceutically acceptable salt or solvate thereof.
• the mammalian subject is a human.
• the contacting is by inhalation.
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising: (i) an antifibrotically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and (ii) a pharmaceutically acceptable carrier or excipient.
• Formula I in the pharmaceutical compositions of the invention is 9-ING-41.
• compositions of the invention are formulated for administration by inhalation.
• the invention is directed to the use of the above compositions for treating IPF in a mammalian subject, wherein an effective amount of said composition is administered to a mammalian subject with IPF.
• the composition inhibits GSK-3P, and inhibits proliferation and/or differentiation of lung myofibroblasts to FL fibroblasts, and reduces proliferation of said FL fibroblasts.
• the composition comprises an effective amount of 9-ING-41 or a pharmaceutically acceptable salt or solvate thereof.
• the mammalian subject is a human.
• the composition is administered by inhalation.
• Another embodiment is directed to use of a composition as above for the manufacture of a medicament for treatment of IPF in a mammalian subject, preferably a human, in need thereof.
• the composition inhibits GSK-3P activity, and inhibits proliferation and/or differentiation of lung myofibroblasts to FL fibroblasts, and reduces proliferation of said FL fibroblasts.
• the compound is preferably 9-ING-41 or a pharmaceutically acceptable salt or solvate thereof.
• the manufacture of the medicament is for administration by inhalation to a human for treatment of IPF.
• FIGs 1A-1B are graphs that show that GSK-3 inhibition with 9-ING-41 attenuated pulmonary fibrosis.
• C57B1/6J mice were intratracheally administered bleomycin sulfate (0.8U/kg). After l4d, mice were either treated with DMSO (vehicle) or the GSK-3P inhibitor, 9-ING-41 (30mg/kg) by dialing intraperitoneal injection for the following l4d.
• DMSO vehicle
• 9-ING-41 30mg/kg
• Figures 4A-4B show lung tissue sections from mice in which TGF-b adenovirus induced pulmonary fibrosis. Mice were treated with DMSO (Fig. 4A) or 9-ING-41 (Fig. 4B) (see Description of Fig. 3). Sections were Tri chrome stained to show areas of injury and collagen. Solid arrows indicate areas of injury and increased collagen deposition. Images are
• FIG. 5A-5F show lung tissue sections (5pm) from vehicle (Fig. 5A-5C)
• FIG. 5D-5F mice.
• Figures 6A-6B show lung sections from vehicle (Fig. 6B) and 9-ING-41 -treated (Fig.
• FIG. 6 mice immunostained for collagen 1 (Col-l) deposition and imaged by confocal microscopy at 40X. Solid arrows indicate areas of collagen deposition within the injured lung. These data show that GSK-3P inhibition with 9ING41 reduced collagen deposition in fibrosing lung injury.
• Figures 7A-7B show lung sections from vehicle (Fig. 7B) and 9-ING-41 -treated (Fig.
• X is independently -H, halo, 5,6-methylenedioxy, -CN, -OMe, -OH, -OBn, -CF 3 , - CH 2 OH, -CH20Me, -CH 2 CH 2 C0 2 H, or -CH 2 CH 2 C0 2 Et;
• R s - H lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with -NH 2 ;
• R 2 is -H, lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with -NH 2 ;
• X is independently -H, halo, 5, 6-methyl enedioxy, -CN, - OMe, -OH, -OBn, -CF 3 , -CH 2 OH, -CH20Me, -CH 2 CH 2 C0 2 H, or -CH 2 CH 2 C0 2 Et.
• Substituent X may be present, independently, at one or more of the positions 4, 5, 6, or 7 of the indole ring in Formula I.
• X is H.
• X is halo (i.e., -F, -Cl, -Br, -I). In some embodiments, X is 5-F.
• X is 5-Br. In other embodiments, X is 5-1.
• X is 5-F, 6-C1. In other embodiments, X is 5,7-dibromo.
• X is 5,6-methylenedioxy.
• X is -CN.
• X is -OMe (i.e., -0-CH 3 )
• X is -OH.
• X is -OBn (i.e., -O-benzyl).
• X is -CF 3
• X is -CH 2 OH.
• X is -CH 2 OMe.
• X is -CH 2 CH 2 C0 2 H.
• X is -CH 2 CH 2 C0 2 Et.
• R 1 is H, lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with -NH 2 .
• R 1 is H.
• R 1 is lower alkyl.
• lower alkyl refers to a saturated, straight chain or branched hydrocarbon group. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, and the like.
• R 1 is -CH 3 (i.e., methyl).
• R 1 is lower alkyl substituted with a hydroxy.
• R 1 is lower alkyl substituted with -NH 2 .
• R 2 is -H, lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with -NH 2 .
• R 2 is H.
• R 2 is lower alkyl. In some embodiments, R 2 is -CH 3 (i.e., methyl). In other embodiments, R 2 is lower alkyl substituted with a hydroxy. In other embodiments, R 2 is lower alkyl substituted with -NH 2.
• Substituent Y may be present, independently, at one or more of the positions 4, 5, 6, or 7 of the benzofuran ring in Formula I.
• Y is H.
• Y is halo (i.e., -F, -Cl, -Br, -I). In some embodiments, Y is 5-F. In other embodiments, Y is 5-Br. In other embodiments, Y is 5-1.
• Y is -CN.
• Y is -OMe (i.e., -0-CH 3 ). In some embodiments, Y is 7-OCH 3
• Y is -OH.
• Y is -OBn (i.e., -O-benzyl).
• Y is -CF 3
• Y is -CH 2 OH. In some embodiments, Y is 6-CH 2 OH.
• Y is -CH 2 OMe.
• Y is -N0 2.
• X is preferably 5,6-methylenedioxy (the substituent in 9-ING-41),
• R 1 is selected from the group consisting of H, lower alkyl, lower alkyl substituted with a hydroxy, lower alkyl substituted with -NH 2 and is preferably methyl;
• R 2 is selected from the group consisting of H, lower alkyl, lower alkyl substituted with a hydroxy, lower alkyl substituted with -NH 2 and is preferably H;
• This embodiment is 9-ING-41, which has the structure shown in Formula II below.
• the compounds of this invention are tested for their biological activity, e.g ., anti-fibrotic activity, their ability to inhibit the enzyme GSK-3P, and/or inhibit proliferating and collagen- producing fibroblasts/myofibroblasts, or of fibrotic lung fibroblasts using any one of the methods or assays described and/or exemplified herein or others that are well-known in the art.
• the ability of a compound to inhibit pulmonary fibrosis in an animal, preferably a mouse, treated with BLM- or constitutively active TGF-b adenoviral vectors is a preferred test for assessing the functional/pharmaceutical activity of the compound.
• Other tests known in the art that measure the same type of activity may also be used.
• the compounds and compositions described herein are used in methods to inhibit the enzyme GSK-3P, to inhibit proliferation of collagen-producing fibroblasts/myofibroblasts vitro or in vivo , and to treat pulmonary fibrosis/IPF.
• the compounds that may be employed in the pharmaceutical compositions of the invention include the compounds described above, preferably 9-ING-41, as well as analogues thereof and pharmaceutically acceptable salts or solvates of these compounds.
• “Pharmaceutically acceptable salt” refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
• Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
• Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetram ethyl ammonium hydroxide.
• Chemical modification of a pharmaceutical compound (i.e., drug) into a salt is a technique well known to pharmaceutical chemists for obtaining improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g ., H. Ansel et al .,
• the compounds of the invention possess the ability to inhibit the enzyme GSK-3P and are exploited in the treatment of pulmonary fibrosis.
• the compounds of the invention may be incorporated into convenient dosage forms, such as capsules, impregnated wafers, tablets or preferably, injectable preparations.
• pharmaceutically acceptable carriers may be employed.
• “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
• Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
• Liquid carriers include syrup, peanut oil, olive oil, saline, water, dextrose, glycerol and the like.
• the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
• the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g, a solution), such as an ampoule, or an aqueous or nonaqueous liquid suspension.
• the pharmaceutical preparations are made following conventional techniques of pharmaceutical chemistry involving such steps as mixing, granulating and compressing, when necessary for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired products for oral, parenteral, topical, transdermal, intravaginal, intrapenile, intranasal, intrabronchial, intracranial, intraocular, intraaural and rectal administration.
• the pharmaceutical compositions may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and so forth.
• the present invention may be used in the treatment of any of a number of animal genera and species, and are equally applicable in the practice of human or veterinary medicine.
• the pharmaceutical compositions can be used to treat domestic and commercial animals, including birds and more preferably mammals, most preferably humans.
• compositions of the present invention may be administered to the subject by any suitable route of administration, including orally, perorally, by inhalation, subcutaneously, intramuscularly, intravenously, transdermally, vaginally, rectally, or in any combination thereof.
• compositions of the present invention are administered orally, perorally, by inhalation, subcutaneously, intramuscularly, or intravenously.
• compositions of the present invention are administered orally.
• compositions of the present invention are administered perorally.
• compositions of the present invention are administered by inhalation.
• compositions of the present invention are administered subcutaneously.
• compositions of the present invention are administered intramuscularly.
• compositions of the present invention are administered intravenously.
• systemic administration refers to administration of the therapeutic compound in a manner that results in the introduction of the compound into the subject’s circulatory system or otherwise permits its spread throughout the body, such as intravenous (i.v.) injection or infusion.
• “Regional” administration refers to administration into a specific, and somewhat more limited, anatomical space, such as instillation or inhalation into the lung, the preferred route, or intrapleural, intraperitoneal, intrathecal, subdural, or to a specific organ.
• Other examples include intranasal, which is one route that corresponds to instillation or inhalation into the lungs, intrabronchial, intra-aural or intraocular, etc.
• local administration refers to administration of a composition or drug into a limited, or circumscribed, anatomic space, such as subcutaneous (s.c.) injections, intramuscular (i.m.) injections.
• s.c. subcutaneous
• i.m. intramuscular
• Instillable, injectable or infusible preparations can be prepared in conventional forms, either as solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection or infusion, or as emulsions.
• the preferred regional routes of administration are into the lungs, the pharmaceutical composition may be administered systemically or topically or transdermally either separately from, or concurrently with, instillation or inhalation into the lungs.
• compositions of the present invention are liposomes, pharmaceutical compositions in which the active polypeptide is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers.
• the active compound is preferably present in the aqueous layer and in the lipidic layer, inside or outside, or, in any event, in the non-homogeneous system generally known as a liposomic suspension.
• the hydrophobic layer, or lipidic layer generally, but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid, and/or other materials of a hydrophobic nature.
• phospholipids such as lecithin and sphingomyelin
• steroids such as cholesterol
• more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid
• the therapeutic dosage administered is an amount which is therapeutically effective, as is known to or readily ascertainable by those skilled in the art.
• the dose is also dependent upon the age, health, and weight of the recipient, kind of concurrent treatment(s), if any, the frequency of treatment, and the nature of the effect desired.
• the methods of this invention may be used to treat pulmonary fibrosis also referred to as IPF in a subject in need thereof.
• the term“treating” is defined broadly to include, at least the following: inhibiting, reducing, ameliorating, preventing, reducing the occurrence or recurrence, including the frequency and/or time to recurrence or the severity of symptoms of the disease or condition being treated or prevented. This may occur as a result of inhibiting epithelial cell death, inhibiting fibroblast proliferation, any of the other biological or biochemical mechanisms disclosed herein as being associated with, or responsible for, IPF.
• the benzofuran-3-yl-(indol-3-yl) maleimide GSK-3P inhibitors i.e., the compounds of Formula I
• 9-ING-41 or pharmaceutically acceptable salt or solvate thereof is preferably administered as a pharmaceutical composition as described above.
• Doses of the compound preferably include pharmaceutical dosage units comprising an effective amount of 9-ING-41.
• Dosage unit form refers to physically discrete units suited as unitary dosages for a mammalian subject; each unit contains a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
• the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of, and sensitivity of, individual subjects
• an effective amount is meant an amount sufficient to achieve a regional concentration or a steady state concentration in vivo which results in a measurable reduction in any relevant parameter of disease.
• antifibrotically effective amount is meant an amount sufficient to inhibit or reduce proliferation and/or differentiation of lung myofibroblasts to fibrotic lung (FL) fibroblasts, or to and reducing proliferation of the FL fibroblasts.
• the amount of active compound to be administered depends on which compound (e.g ., 9-ING-41) is selected, the precise disease or condition, the route of administration, the health and weight of the recipient, the existence of other concurrent treatment, if any, the frequency of treatment, the nature of the effect desired, and the judgment of the skilled practitioner.
• a preferred single dose, given once daily for treating a subject, preferably a mammal, more preferably human who is suffering from or susceptible to IPF resulting therefrom is between about 0.2 mg/kg and about 250 mg/kg, (for example, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, or 250 mg/kg of active compound), between about 0.2 mg/kg and about 10 mg/kg; between about 0.5 mg/kg and about 5 mg/kg; between about 1 mg/
• Such a dose can be administered daily for anywhere from about 3 days to one or more weeks. Chronic administration is also possible, though the dose may need to be adjusted downward as is well-understood in the art.
• the foregoing ranges are, however, suggestive, as the number of variables in an individual treatment regimen is large, and considerable excursions from these preferred values are expected.
• a total dosage for a time course of about 1-2 weeks is preferably in the range of 1 mg/kg to 1 g/kg (e.g, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80,
• the total concentration of the active compound is preferably in the range of about 0.5 to about 50 mM ( e.g ., 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 pM), preferably about 1 to about 10 pM.
• An effective concentration of the active compound for inhibiting GSK-3P or preventing myofibroblast and fibrotic lung fibroblast proliferation in vitro is in the range of about 0.5 pM to about 100 pM (e.g., 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 pM), more preferably from about 2 pM to about 20 pM. Effective concentrations, doses and optimal dose ranges may be determined in vitro using the methods described herein.
• the compounds or compositions may be administered to the subject by any suitable route of administration, including orally, perorally, by inhalation, subcutaneously, intramuscularly, intravenously, transdermally, vaginally, rectally, or in any combination thereof.
• the compounds or compositions are administered orally, perorally, by inhalation, subcutaneously, intramuscularly, or intravenously.
• the compounds or compositions are administered orally.
• the compounds or compositions are administered perorally.
• the compounds or compositions are administered by inhalation.
• the compounds or compositions are administered subcutaneously.
• the compounds or compositions are administered intramuscularly.
• the compounds or compositions are administered intravenously.
• IP intraperitoneal
• mice were evaluated by flexivent (Tucker T et al., Am J Respir Cell Mol Biol 2019 (doi: l0.H65/rcmb.20l8-0l2lOC. Epub ahead of print); Kamata H et al, Sci Rep 2017, 7:4556; Boren J et al., supra ; Tucker TA et al, 2014, supra ; Tucker TA et al, Clin TranslMed 5: 17, 2016) for changes in pulmonary function including elastance and compliance. Briefly, mice were anesthetized with a ketamine/xylazine mixture.
• mice were intubated by inserting a sterile, 20-gauge intravenous cannula through the vocal cords into the trachea and were maintained under anesthesia using isoflurane during pulmonary function testing. Measurements were performed using the flexiVent system (SCIREQ, Tempe A Z). The“snapshot perturbation method” was used to determine lung compliance, according to manufacturer’s specifications. At 28d, mice were euthanized and lungs harvested en bloc. Lung morphometry was determined by tri chrome staining of 5pm lung tissue sections as described in the above cited references. All tissue sections were first de-paraffmized and subjected to antigen retrieval using a citrate buffer at 95°C for 20 minutes.
• Ad-TGF-b constitutively active TGF-b adenoviral vectors bearing C223S/C225S mutations, as reported by Mackinnon AC et al, Am J Respir Crit Care Med 2012, 185:537-46) with some modifications.
• Ad-eGFP constitutively active TGF-b adenoviral vectors bearing C223S/C225S mutations
• 3 x 10 8 pfu of Ad-TGF-b or eGFP adenovirus control vector (Ad-eGFP) were administered intratracheally in a volume of 40 m ⁇ . Mice were then monitored daily until the completion of the l4d time-course.
• mice received daily 9- ING-41 treatment 7d after administration of the adenoviral vectors.
• pulmonary function testing and CT scans were performed as described (Tucker T et al, 2019, supra ; Kamata H et al, 2017, supra ; Boren J et al, 2017, supra ; Tucker TA et al, 2016, supra.
• 9-ING-41 improves bleomycin mediated decrements of lung function and volume.
• Figs. 1 A-1B GSK-3 inhibition with 9-ING-41 attenuated pulmonary fibrosis.
• Drugs were delivered via intraperitoneal (ip) injection in a volume of 40m1 for up to l4d.
• ip intraperitoneal
• lung compliance was determined using the Scireq flexivent. Lung renditions were also collected by gated CT scan. These renditions were then used to determine lung volumes.
• Fibrotic foci consistent with bleomycin-induced pulmonary fibrosis were found throughout the injured lung. Areas of matrix deposition were readily and uniformly present throughout the lung. 9-ING-41 treated mice also demonstrated areas of injury; however, these areas were fewer in number and smaller compared to those found in the vehicle treated animals. Further, collagen deposition within the fibrotic lesions was generally reduced in 9-ING-41- treated mice (Fig. 2A) compared to DMSO-treated controls (Fig. 2B). See, also , Figs. 5A-5F.
• Pulmonary fibrosis was initiated by intratracheal instillation of constitutively active TGF-b adenoviral vectors (Ad-TGF-b) bearing C223S/C225S mutations, as previously reported (Mackinnon AC et al, Am J Respir Crit Care Med 2012, 185:537-46) with some modifications. Briefly, 3 x 10 8 plaque forming units (pfu) of Ad-TGF-b or eGFP adenovirus control vector (Ad- eGFP) were administered intratracheally in a volume of 40 m ⁇ . Mice were then monitored daily until the completion of the l4d time-course.
• Ad-TGF-b constitutively active TGF-b adenoviral vectors bearing C223S/C225S mutations
• mice received daily 9-ING-41 treatment 7d after administration of the adenoviral vectors.
• 9-ING-41 treatment 7d After administration of the adenoviral vectors.
• pulmonary function testing and CT scans were performed as described (Tucker T et al, 2019, supra ; Kamata H et al, 2017, supra ; Boren J et al, 2017, supra ; Tucker TA et al, 2016, supra.
• IPF is characterized by the increased presence of myofibroblasts and subsequent increased deposition of extracellular matrix (ECM) proteins such as collagen and fibronectin.
• ECM extracellular matrix
• bleomycin sulfate and TGF-b adenovirus was introduced by intratracheal cannulation, a method that yields robust and consistent injury (thus requiring fewer animals to yield statistically significant results).
• Bleomycin- and TGF ⁇ -adenovirus-mediated fibrosis were characterized by the presence of fibrotic foci that contained collagen and other ECM matrix protein which contribute to lung scarring, loss of the normal lung architecture, and impaired lung function. Further, these fibrotic foci also contained increasing numbers of myofibroblasts, which are believed to be the primary source of increased ECM deposition.
• 9-ING-41 IPF To evaluate the efficacy of the preferred GSK ⁇ inhibitory compound, 9-ING-41 IPF, intervention was done at a time point at which alterations of pulmonary architecture and function were detectable. Based on preliminary studies, the l4d time-point was selected for bleomycin injury studies and 7d for TGF-b adenoviral studies. By completion of the time courses (28d and l4d respectively) 9-ING-41 treated mice in both models not only manifested improved lung function but also showed increased lung volume. Based on the histopathological analyses discussed and exemplified above, the present inventors concluded that the reduced number of fibrotic foci in combination with reduced scarring contributed to restoration of lung function as a result of 9-ING-41 treatment.
• the present disclosure also encompasses the following aspects:
• An antifibrotic pharmaceutical composition formulated for injection or lung instillation comprising:
• synthase kinase 3, form b (GSK3P), which has at least at least 20% of the biological or biochemical activity of 9-ING-41 in an in vitro or in vivo assay.
• 9-ING-41 which has at least 20% of the biological or biochemical activity of 9-ING-41 in an in vitro or in vivo assay.
• Aspect 3 The pharmaceutical composition of aspect 2 wherein the compound is
• Aspect 4 The pharmaceutical composition of any of aspects 1 to 3 formulated for lung instillation.
• a method for inhibiting proliferation and/or differentiation of lung myofibroblasts to fibrotic lung (FL) fibroblasts and reducing proliferation of said FL fibroblasts comprising providing to said myofibroblasts and FL fibroblasts an effective GSIOP-inhibitory amount of the compound or composition of any of aspects 1-4.
• Aspect 6 The method of aspect 5 wherein the compound is 9-ING-41 or said analogue thereof.
• Aspect 7 The method of aspect 6 wherein the compound is 9-ING-41.
• Aspect 8 The method of aspect 7 wherein the composition is formulated for lung instillation.
• Aspect 9 The method of any of aspects 5 to 8 wherein said providing is in vivo.
• Aspect 10 The method of aspect 9 wherein said providing is by lung instillation.
• Aspect 11 The method of aspect 9 or 10 wherein said providing is to a human.
• IPF idiopathic pulmonary fibrosis
• Aspect 13 The method of aspect 12 wherein said compound or composition comprises 9-ING-41 or said analogue thereof that has at least 20% of the biological or biochemical activity of 9-ING-41 in an in vitro or in vivo assay;
• Aspect 14 The method of aspect 13, wherein the compound is 9-ING-41.
• Aspect 15 The method of any one of aspects 12 to 14 wherein the subject is a human.
• Aspect 16 A use of the composition of any of aspects 1 to 4 for treating IPF in a mammalian subject, wherein said compound inhibits GSIOp and inhibits proliferation and/or differentiation of lung myofibroblasts to FL fibroblasts and reduces proliferation of said FL fibroblasts, and an effective amount of said composition is administered to a subject with IPF.
• Aspect 17 The use according to aspect 16 wherein said compound is 9-ING-41 or said analogue thereof.
• Aspect 18 The use according to aspect 17 wherein said compound is 9-ING-41.
• Aspect 19 The use according to any of aspects 16-18 where said composition is administered by lung instillation.
• Aspect 20 The use of a composition according to of aspects 1-4 for the manufacture of a medicament for treatment of IPF in a subject in need thereof, which compound inhibits GSK3p activity and inhibits proliferation and/or differentiation of lung myofibroblasts to FL fibroblasts and reduces proliferation of said FL fibroblasts.
• Aspect 21 The use according to aspect 20 wherein said compound is 9-ING-41 or an analogue thereof that has at least 20% of the biological or biochemical activity of 9-ING-41 in an in vitro or in vivo assay.
• Aspect 22 The use according to aspect 21 wherein said compound is 9-ING-41.
• Aspect 23 The use according to any of aspects 20-22 for the manufacture of the medicament for lung instillation in the treatment of IPF.
• Aspect 24 The use according to any of aspects 20-24 wherein the subject is a human.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Otolaryngology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=68541026

Family Applications (1)

Country Status (11)

Cited By (2)

Families Citing this family (1)

Citations (1)

Family Cites Families (11)

• 2019
  • 2019-05-16 WO PCT/US2019/032639 patent/WO2019222483A1/en not_active Ceased
  • 2019-05-16 MX MX2020012331A patent/MX2020012331A/es unknown
  • 2019-05-16 IL IL278761A patent/IL278761B2/en unknown
  • 2019-05-16 CA CA3100381A patent/CA3100381A1/en active Pending
  • 2019-05-16 CN CN201980041162.0A patent/CN112437663A/zh active Pending
  • 2019-05-16 EP EP19803888.7A patent/EP3793545A4/en not_active Withdrawn
  • 2019-05-16 JP JP2021514939A patent/JP7471660B2/ja active Active
  • 2019-05-16 AU AU2019271285A patent/AU2019271285B2/en active Active
  • 2019-05-16 KR KR1020207035908A patent/KR20210038429A/ko not_active Ceased
  • 2019-05-16 BR BR112020023422-2A patent/BR112020023422A2/pt unknown
  • 2019-05-16 US US17/056,238 patent/US12083098B2/en active Active
• 2024
  • 2024-02-16 JP JP2024021588A patent/JP2024069221A/ja active Pending

Patent Citations (2)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events